Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | helveticoside | 441860 | drug-path |
| B cell receptor signaling pathway | R-HSA-983705 | map04662 | lanatoside C | 656630 | drug-path |
| Alzheimer's disease | R-HSA-1643685 | 0 | lanatoside C | 656630 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | lanatoside C | 656630 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | lanatoside C | 656630 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | lanatoside C | 656630 | drug-path |
| Bladder cancer | R-HSA-9700206 | map05219 | lanatoside C | 656630 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | lanatoside C | 656630 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | lanatoside C | 656630 | drug-path |
| Ribosome | R-HSA-5368277 | map03010 | lanatoside C | 656630 | drug-path |
| Chronic myeloid leukemia | R-HSA-9680350 | map05220 | lanatoside C | 656630 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | lanatoside C | 656630 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | lanatoside C | 656630 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | lanatoside C | 656630 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | lanatoside C | 656630 | drug-path |
| Taste transduction | R-HSA-162582 | map04742 | lanatoside C | 656630 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | lanatoside C | 656630 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | lanatoside C | 656630 | drug-path |
| Leukocyte transendothelial migration | R-HSA-8950732 | map04670 | lanatoside C | 656630 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | lanatoside C | 656630 | drug-path |